Abstract:Background CD4+CD25+Foxp3+ T regulatory (Treg) cells play a key role in peripheral tolerance. Rapamycin was approved by the FDA to preserve renal allografts and to be efficacious in patients with several autoimmune diseases [1]. Objectives To investigate the status of Treg cells in active refractory rheumatoid arthritis (RA) and the effects of rapamycin on patients with RA. Methods Forty-five active refractory RA patients were enrolled. Rapamycin was used at a dose of 0.5 mg every 2 days [the preliminary, open-label clinical trial of rapamycin (Clinical Trials.gov number: ChiCTR-IPR-17010307)]. Clinical improvement and immunological assessments were performed before 1st rapamycin dose and 12 weeks post treatment. Blood samples were obtained from RA patients and 75 healthy volunteers for estimation of CD4+ T cell subsets. Results Two patients dropped out due to non-compliance. As compared to healthy controls (median of Treg cells: 33.32 cell/ul), the absolute counts of circulating Treg cells were significantly decreased in patients with active refractory RA (median: 27.17 cell/ul; P=0.046). While the median ratios of Th17/Treg cells in patients with active refractory RA (median: 0.26) were significantly higher than those of healthy volunteers (median: 0.19; P=0.029). No difference in the absolute counts of circulating Th17 cells and Th1 cells was observed between patients with active refractory RA and healthy subjects. Rapamycin treatment led to clinical improvement with the median post-treatment DAS28-ESR decreasing when compared to baseline (from 4.19 to 3.78) in active refractory RA patients. Sixteen patients (16/43 patients, 37.21%) achieved an EULAR moderate response and 6 patients (6/43 patients, 13.95%) reached good response at week 12. Rapamycin administration resulted in an increase in the absolute counts of Treg cells in active refractory RA patients, from a median of 27.17 cell/ul (at week 0) to 37.57 cell/ul (at week 12) (P=0.041). The ratios of Th17/Treg cells shows a reduction from a median of 0.26 at baseline to 0.20 at week 12, but the difference is not significant (P =0.376). No significant difference was observed in the absolute counts of circulating Th17 and Th1 cells after rapamycin treatment. Interestingly, we observed that Treg cells increased before the complete remission of the disease (DAS28 score <2.6) in patients with active refractory RA. At week 12, the mean dose of prednisone which refractory RA patients were receiving decreased from 11.98 mg/d to 8.31 mg/d, with a dose reduced by ≥30% than that at baseline. The categories of DMARDs use were also reduced (P<0.05). No serious adverse events was observed during the 12-week period of rapamycin treatment. Conclusions Reduced absolute number of Treg cells was found in the patients with active refractory RA, indicating an imbalance between Th17 and Treg cells. Rapamycin elicits rapid improvement of disease activity via restoring circulating Treg cells numbers in patients with active refractory RA. References Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016. 12(3): 169–82. Disclosure of Interest None declared

Rapamycin Controls Lymphoproliferation and Reverses T-Cell Responses in a Patient with a Novel STIM1 Loss-of-Function Deletion

FRI0063 Rapamycin Induces Remission in Patients with Refractory Rheumatoid Arthritis

AB0421 Rapamycin Reduces Disease Activity Through Restoring Regulatory T Cell Numbers in Patients with Active Refractory Rheumatoid Arthritis

THU0176 Efficiency and safety of rapamycin combined with low-dose IL-2 treatment compared with methotrexate in patients with rheumatoid arthritis

Rapamycin-resistant effector T-cell therapy

Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome

Rapamycin Induces Phenotypic Alterations in Oral Cancer Cells That May Facilitate Antitumor T Cell Responses

Efficacy and Safety of Mtor Inhibitors (rapamycin and Its Analogues) for Tuberous Sclerosis Complex: a Meta-Analysis

AB0382 Rapamycin Selectively Increases Circulating Tregcellsand Maintain Remission of Patients with Rheumatoid Arthritis

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1

mTOR inhibition alleviates CD8+ T-cell senescence in activated phosphoinositide 3-kinase δ syndrome 2 patients

Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment

Rapamycin Inhibits Hepatic Stellate Cell Proliferation in Vitro and Limits Fibrogenesis in an in Vivo Model of Liver Fibrosis

Deep phenotyping of T cell populations under long-term treatment of tacrolimus and rapamycin in patients receiving renal transplantations by mass cytometry

AB0376 Rapamycin induces remission in patients with newly diagnosed rheumatoid arthritis

Genetic defects in SAPK signalling, chromatin regulation, vesicle transport and CoA-related lipid metabolism are rescued by rapamycin in fission yeast

Rapamycin Inhibiting Jurkat T Cells Viability Through Changing Mrna Expression of Serine/Threonine Protein Phosphatase 2A

Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain

Combined Therapy of Prednisone and Mtor Inhibitor Sirolimus for Treating Retroperitoneal Fibrosis

RapaLink-1 Outperforms Rapamycin in Alleviating Allogeneic Graft Rejection by Inhibiting the Mtorc1-4E-bp1 Pathway in Mice.

Rapamycin Interacts Synergistically with Idarubicin to Induce T-Leukemia Cell Apoptosis in Vitro and in A Mesenchymal Stem Cell Simulated Drug-Resistant Microenvironment Via Akt/Mammalian Target of Rapamycin and Extracellular Signal-Related Kinase Signaling Pathways